International Histopathology Consensus for Unilateral Primary Aldosteronism.
Adrenal Glands
/ metabolism
Adrenalectomy
/ methods
Adult
Cohort Studies
Consensus
Cytochrome P-450 CYP11B2
/ metabolism
Cytodiagnosis
/ methods
Diagnostic Techniques, Endocrine
/ standards
Female
Germany
Histological Techniques
/ standards
Humans
Hyperaldosteronism
/ complications
Hypertension
/ diagnosis
Immunohistochemistry
Internationality
Male
Middle Aged
Practice Guidelines as Topic
/ standards
Societies, Medical
/ standards
CYP11B2
adrenal gland
diagnostic histopathology
immunohistochemistry
primary aldosteronism
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
10
06
2020
accepted:
20
07
2020
pubmed:
28
7
2020
medline:
4
9
2021
entrez:
28
7
2020
Statut:
ppublish
Résumé
Develop a consensus for the nomenclature and definition of adrenal histopathologic features in unilateral primary aldosteronism (PA). Unilateral PA is the most common surgically treated form of hypertension. Morphologic examination combined with CYP11B2 (aldosterone synthase) immunostaining reveals diverse histopathologic features of lesions in the resected adrenals. Surgically removed adrenals (n = 37) from 90 patients operated from 2015 to 2018 in Munich, Germany, were selected to represent the broad histologic spectrum of unilateral PA. Five pathologists (Group 1 from Germany, Italy, and Japan) evaluated the histopathology of hematoxylin-eosin (HE) and CYP11B2 immunostained sections, and a consensus was established to define the identifiable features. The consensus was subsequently used by 6 additional pathologists (Group 2 from Australia, Brazil, Canada, Japan, United Kingdom, United States) for the assessment of all adrenals with disagreement for histopathologic diagnoses among group 1 pathologists. Consensus was achieved to define histopathologic features associated with PA. Use of CYP11B2 immunostaining resulted in a change of the original HE morphology-driven diagnosis in 5 (14%) of 37 cases. Using the consensus criteria, group 2 pathologists agreed for the evaluation of 11 of the 12 cases of disagreement among group 1 pathologists. The HISTALDO (histopathology of primary aldosteronism) consensus is useful to standardize nomenclature and achieve consistency among pathologists for the histopathologic diagnosis of unilateral PA. CYP11B2 immunohistochemistry should be incorporated into the routine clinical diagnostic workup to localize the likely source of aldosterone production.
Identifiants
pubmed: 32717746
pii: 5876946
doi: 10.1210/clinem/dgaa484
pmc: PMC7765663
doi:
Substances chimiques
Cytochrome P-450 CYP11B2
EC 1.14.15.4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-54Subventions
Organisme : BLRD VA
ID : I01 BX004681
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK106618
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL144847
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM115428
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Hypertension. 2020 Mar;75(3):634-644
pubmed: 31957522
Hypertension. 2010 Nov;56(5):885-92
pubmed: 20937967
Steroids. 1995 Jan;60(1):35-41
pubmed: 7792813
Clin Endocrinol (Oxf). 2015 May;82(5):639-47
pubmed: 25347939
Horm Metab Res. 2017 Dec;49(12):957-962
pubmed: 29202495
Mol Cell Endocrinol. 2014 Jul 5;392(1-2):73-9
pubmed: 24837548
Clin Endocrinol Metab. 1985 Nov;14(4):791-820
pubmed: 3002677
Hypertension. 2018 Sep;72(3):650-657
pubmed: 30012870
Eur J Endocrinol. 2018 Jul;179(1):R19-R29
pubmed: 29674485
Lancet. 1992 Jul 18;340(8812):159-61
pubmed: 1352575
Pathol Int. 2017 Apr;67(4):214-221
pubmed: 28261922
J Clin Endocrinol Metab. 2010 May;95(5):2296-305
pubmed: 20200334
Mol Cell Endocrinol. 2014 Mar 5;383(1-2):111-7
pubmed: 24325867
J Clin Endocrinol Metab. 2012 May;97(5):E819-29
pubmed: 22442279
Endocr Rev. 2018 Dec 1;39(6):1029-1056
pubmed: 30007283
Mol Cell Endocrinol. 2015 Aug 15;411:146-54
pubmed: 25958045
Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699
pubmed: 28576687
Physiol Rev. 2016 Oct;96(4):1327-84
pubmed: 27535640
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50
pubmed: 29129575
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1182-1192
pubmed: 28388725
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31789380
Hypertension. 2018 Sep;72(3):632-640
pubmed: 30354756
Lancet Diabetes Endocrinol. 2018 Jan;6(1):51-59
pubmed: 29129576
Nat Rev Endocrinol. 2013 Feb;9(2):104-12
pubmed: 23229280
Hypertension. 2018 Oct;72(4):874-880
pubmed: 30354720
Hypertension. 2015 Nov;66(5):1014-22
pubmed: 26351028
J Clin Endocrinol Metab. 2016 Jan;101(1):6-9
pubmed: 26580238
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4591-9
pubmed: 26240369
J Clin Pathol. 2013 Apr;66(4):351-4
pubmed: 23436930